BioXcel Therapeutics CEO to participate in virtual fireside chat on Aug 14, 2025.

BioXcel Therapeutics CEO Vimal Mehta will participate in a virtual fireside chat on August 14, 2025, as part of H.C. Wainwright & Co.'s "HCW@Home" series. The biopharmaceutical company utilizes artificial intelligence to develop transformative medicines in neuroscience, with a focus on the development of medicines in immuno-oncology.

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company leveraging artificial intelligence to develop transformative medicines in neuroscience, has announced that CEO Vimal Mehta, Ph.D., will participate in a virtual fireside chat as part of H.C. Wainwright & Co.'s "HCW@Home" series. The event, scheduled for Thursday, August 14, 2025, at 1:00 p.m. ET, will provide insights into the company's operations and developments.

The company, which utilizes artificial intelligence to discover and develop innovative medicines, is focused on the development of medicines in immuno-oncology. Its wholly owned subsidiary, OnkosXcel Therapeutics, is dedicated to the development of medicines in this area. BioXcel Therapeutics employs a drug re-innovation approach, combining existing approved drugs and clinically validated product candidates with big data and proprietary machine learning algorithms to identify new therapeutic indications.

The upcoming fireside chat will offer investors and financial professionals the opportunity to engage with Vimal Mehta and learn more about BioXcel Therapeutics' strategic initiatives and clinical advancements. The company has recently reported its financial results for the second quarter of 2025 and announced the completion of its SERENITY At-Home pivotal Phase 3 safety trial for acute treatment of agitation associated with bipolar disorders or schizophrenia. Topline results from this trial are expected in August and are intended to support a potential submission for label expansion of IGALMI® in the at-home setting.

Additionally, BioXcel Therapeutics is exploring the potential applications of BXCL501 in chronic conditions, with recent research published in the journal Frontiers in Pharmacology suggesting the drug's mechanism of action in reducing stress-induced behaviors related to psychiatric disorders. The company is also strengthening its cash position and evaluating CROs for trial initiation in its TRANQUILITY In-Care Phase 3 trial for acute treatment of agitation associated with Alzheimer’s dementia.

Investors and financial professionals are encouraged to register for the virtual fireside chat to gain a deeper understanding of BioXcel Therapeutics' progress and future plans.

References:
[1] https://www.stocktitan.net/news/BTAI/bio-xcel-therapeutics-to-participate-in-the-h-c-wainwright-co-hcw-fixzi4mnp2wv.html
[2] https://ir.bioxceltherapeutics.com/news-releases/news-release-details/bioxcel-therapeutics-reports-second-quarter-2025-financial